Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study | Leukemia
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
VALIDATED STABILITY INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF DAUNORUBICIN AND CYTARABINE IN BULK AND ITS PHARMACEUTICAL DOSAGE FORM | Semantic Scholar
A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model - ScienceDirect
VALIDATED STABILITY INDICATING RP-HPLC METHOD FOR SIMULTANEOUS ESTIMATION OF DAUNORUBICIN AND CYTARABINE IN BULK AND ITS PHARMACEUTICAL DOSAGE FORM | Semantic Scholar
Primary AML cells and cell lines resistant to cytarabine, daunorubicin... | Download Scientific Diagram
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - ScienceDirect
Therapy protocol Slika 1. Protokol terapije * daunorubicin 45 mg/m 2 or... | Download Scientific Diagram
Cureus | Resistance Mechanism of Acute Myeloid Leukemia Cells Against Daunorubicin and Cytarabine: A Literature Review | Article
Secondary AML Treatment | VYXEOS® (daunorubicin and cytarabine)
PDF) Outcome of Standard Induction Therapy with Daunorubicin and Ara-C (3+7) in Acute Myeloid Leukemia | Akhil Biswas - Academia.edu
Fernand Bteich on X: "13/ Typical induction regimen is 7+3. Total is 7 days with 3 days of overlap. 7 days of cytarabine infusion. 3 days of anthracycline infusion (daunorubicin or idarubicin).
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - Annals of Oncology
Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51 | PLOS ONE
Daunorubicin/cytarabine - Wikipedia
Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells | PNAS
Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial - The Lancet Haematology
Determination of free and encapsulated cytarabine and daunorubicin in rat plasma after intravenous administration of liposomal formulation using ultra-high performance liquid chromatography tandem mass spectrometry - ScienceDirect
Targeted co-delivery of daunorubicin and cytarabine based on the hyaluronic acid prodrug modified liposomes
Acute myeloid leukaemia (AML) and cytarabine pharmacogenomics
Effect of Ara-C, daunorubicin, mitoxantrone and etoposide on the... | Download Scientific Diagram
Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells | Scientific Reports
CPX-351 versus 7+3 cytarabine and daunorubicin chemotherapy in older adults with newly diagnosed high-risk or secondary acute myeloid leukaemia: 5-year results of a randomised, open-label, multicentre, phase 3 trial - The Lancet
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia | Leukemia
IJMS | Free Full-Text | Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine
